Andrew Engdahl, the Head of Sales at the post-click automation platform Instapage, has been officially nominated as a candidate for the Blood Cancer United Visionaries of the Year campaign. This prestigious nomination recognizes professional leaders who leverage their personal influence and corporate platforms to generate significant funding and awareness for blood cancer research and patient support services. Engdahl’s candidacy is not merely a philanthropic endeavor but a continuation of a deeply personal battle with Stage 4 Non-Hodgkin’s Lymphoma, a diagnosis that transformed his perspective on leadership, resilience, and corporate responsibility. As a survivor now in his third year of remission, Engdahl has launched a high-profile campaign with a fundraising goal of $50,000, timed to coincide with global awareness efforts following World Cancer Day.
The nomination highlights a growing trend within the technology and SaaS (Software as a Service) sectors, where high-level executives are increasingly utilizing their professional networks to address systemic health challenges. At Instapage, Engdahl has been instrumental in the company’s commercial scaling, overseeing the acquisition of major accounts and leading a global sales force. His transition from a life-threatening medical crisis to a leadership role serves as a case study in professional endurance. The Visionaries of the Year program, managed by the Leukemia & Lymphoma Society (LLS) and its affiliates, selects candidates based on their community standing and their ability to lead large-scale "man and woman of the year" style fundraising initiatives that typically span a ten-week period.
A Chronology of Crisis and Recovery: The 2022 Diagnosis
The trajectory of Andrew Engdahl’s advocacy began in the summer of 2022, a period that initially appeared to be a standard chapter in his professional career at Instapage. The onset of his illness was deceptive, manifesting as what Engdahl described as simple muscle tension—a common complaint for high-performance professionals. However, the rapid escalation of symptoms soon revealed a much more catastrophic reality. Medical evaluations led to a diagnosis of Stage 4 Non-Hodgkin’s Lymphoma, a form of cancer that originates in the lymphatic system, which is part of the body’s immune system. In Stage 4, the cancer has typically spread to organs outside the lymph system, such as the liver, lungs, or, in Engdahl’s case, the bone marrow and surrounding structures.
The clinical intervention required to address the advanced stage of the disease was exhaustive and invasive. The medical timeline involved major spinal surgery to address complications arising from the malignancy, followed by four lumbar punctures—a procedure used to collect cerebrospinal fluid or inject medications directly into the spinal canal. To combat the systemic spread of the lymphoma, Engdahl underwent six rounds of chemotherapy infusions. These treatments, while necessary for survival, often result in significant physical depletion.
Following the acute medical phase, Engdahl entered a rigorous six-month period of rehabilitation. This phase was defined by intensive physical therapy and yoga, which were essential for regaining the mobility and strength lost during the surgery and chemical treatments. This period of "relearning" physical autonomy became the foundation for his current philosophy on resilience. By the time he reached the three-year remission milestone, Engdahl had not only returned to his duties at Instapage but had ascended to lead the sales department, integrating his survival experience into his management style.
Understanding Non-Hodgkin’s Lymphoma: Supporting Data and Context
To understand the weight of Engdahl’s campaign, it is necessary to examine the broader context of blood cancers in the United States and globally. Non-Hodgkin’s Lymphoma (NHL) is one of the most common cancers in the United States, accounting for about 4% of all cancers. According to data from the American Cancer Society, an estimated 80,620 people are diagnosed with NHL annually, with approximately 20,140 deaths attributed to the disease each year.
The survival rates for NHL vary significantly based on the subtype and the stage at diagnosis. While the overall five-year relative survival rate for NHL is approximately 74%, that figure can fluctuate for Stage 4 diagnoses. However, advancements in immunotherapy and targeted chemotherapy—research funded by initiatives like Visionaries of the Year—have drastically improved outcomes for late-stage patients over the last decade. The financial burden of these treatments is substantial; a 2022 study on the economic impact of cancer indicated that blood cancer patients often face some of the highest out-of-pocket costs in the healthcare system due to the longevity and intensity of treatment cycles.
Engdahl’s $50,000 fundraising goal is designed to mitigate these burdens. Funds raised through the Visionaries of the Year program are typically allocated to three primary pillars:
- Research: Funding scientists who are developing the next generation of blood cancer treatments, such as CAR-T cell therapy.
- Patient Support: Providing financial assistance to families to cover travel, co-pays, and medication costs.
- Advocacy: Lobbying for policy changes that ensure cancer patients have access to affordable, high-quality care.
The Intersection of Corporate Leadership and Philanthropy
Engdahl’s role at Instapage provides a unique vantage point for his advocacy. As Head of Sales, he operates in an environment defined by metrics, growth, and competition. However, his campaign emphasizes "paying it forward," a concept that suggests corporate success is incomplete without a corresponding social contribution. Instapage has publicly supported Engdahl’s nomination, signaling a corporate culture that values the holistic well-being of its executives and the broader community.
Statements from the company suggest that Engdahl’s journey has influenced the internal culture at Instapage. "Andrew brings a genuine sense of joy and optimism to the company," the organization noted in a recent announcement. This sentiment reflects a shift in the tech industry toward "authentic leadership," where executives are encouraged to share their personal challenges to build trust and morale within their teams. By using his platform to discuss his Stage 4 diagnosis, Engdahl humanizes the executive suite and provides a roadmap for employees facing their own personal or health-related crises.
The campaign was strategically announced on World Cancer Day, an international awareness day led by the Union for International Cancer Control (UICC). World Cancer Day aims to prevent millions of deaths each year by raising awareness and education about cancer and pressing governments and individuals across the world to take action. By aligning his personal goal with this global event, Engdahl tapped into a worldwide conversation about the "equity gap" in cancer care—the idea that many patients do not have access to the life-saving treatments that allowed him to reach remission.
Broader Implications and the Path to Remission
The implications of Engdahl’s campaign extend beyond the immediate $50,000 goal. His story highlights the critical importance of early detection and the efficacy of modern oncology. In many cases, the symptoms of lymphoma are non-specific, often mistaken for minor ailments or stress-related tension. Engdahl’s experience serves as a cautionary tale and a call to action for high-stress professionals to prioritize medical screenings.
Furthermore, the Visionaries of the Year campaign serves as a mechanism for "community-led research." Unlike government grants, which can be slow and bureaucratic, the funds raised by candidates like Engdahl are often more agile, allowing for the funding of high-risk, high-reward research projects that might otherwise go unfunded. Historically, the Leukemia & Lymphoma Society has played a role in nearly every breakthrough in blood cancer treatment, including those that have crossed over to benefit patients with solid tumors, such as breast and colon cancer.
As Engdahl moves forward with his campaign, the focus remains on the "Visionary" aspect of the nomination. To be a visionary in this context is to see a future where a Stage 4 diagnosis is no longer a death sentence but a manageable condition. His commitment to "making a difference while I still have the strength and ability to do so" underscores the urgency of the fight against blood cancer.
Conclusion and Future Outlook
Andrew Engdahl’s transition from a patient navigating spinal surgery and chemotherapy to a candidate for Visionary of the Year marks a significant chapter in his career and personal life. As the Head of Sales at Instapage, he continues to drive the company’s commercial success while simultaneously leading a charge against the "scourge of blood cancer."
The success of his $50,000 campaign will contribute to a larger pool of resources dedicated to eradicating Non-Hodgkin’s Lymphoma and supporting those currently in the midst of the struggle. For the tech industry and the wider business community, Engdahl’s journey provides a profound example of how personal adversity can be synthesized into a powerful tool for social good. The campaign continues through the spring, with final fundraising totals and the announcement of the Visionary of the Year winner expected at the conclusion of the ten-week period. For now, Engdahl remains focused on his dual mission: leading his team at Instapage and ensuring that his "second chance at life" is used to provide the same opportunity for others.
